Drug pricing regulator NPPA revises ceiling prices of 128 medicines

As per the notification, the ceiling price of one Amoxicillin capsule has been fixed at Rs 2.18; one tablet of Cetirizine at Rs 1.68

Press Trust of India
2 min read Last Updated : Jan 17 2023 | 12:06 AM IST
Drug pricing regulator National Pharmaceutical Pricing Authority has revised prices of 128 drugs, including antibiotics and antiviral medications.

The formulations for which the ceiling price has been fixed include antibiotic injections of Amoxicillin and Clavulanic acid; Vancomycin, asthma medication Salbutamol, cancer drug Trastuzumab, brain tumour treatment drug Temozolomide, painkiller Ibuprofen and paracetamol which is used to treat pain and fever.

As per the notification, the ceiling price of one Amoxicillin capsule has been fixed at Rs 2.18; one tablet of Cetirizine at Rs 1.68; Amoxicillin and Clavulanic acid injection at Rs 90.38; Ibuprofen 400 mg tablet at Rs 1.07.

Also Read

"All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the government, shall revise the prices of all such formulations downward not exceeding the ceiling price," the notification said.

The National Pharmaceutical Pricing Authority (NPPA) has also fixed the retail price of 12 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022). The retail price of one tablet of anti-diabetes combination drug Glimepiride, Voglibose & Metformin (extended release) has been fixed at Rs 13.83.

Similarly, retail price of one tablet of Paracetamol, Phenylephrine Hydrochloride, Diphenhydramine Hydrochloride and Caffeine has been fixed at Rs 2.76.

Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of DPCO and monitoring of prices of controlled and decontrolled drugs. 
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :NPPAMedicinespharmacy

Next Story